Tell us a bit about yourself

My education is from Harvard College in Biomedical engineering. My education focused mostly on prosthetic and exoskeleton development as well drug delivery and synthetic tissue development. I wanted to be a part of a field that would directly have results on the health and well being of people. There is so much incredible technology in the world and I wanted to learn to leverage these skill sets to develop solutions with tangible impact.

How do you find working Hercules?

The work culture at Hercules is absolutely fantastic. It is filled with intelligent and passionate individuals who want to make a change in this industry. Despite this mentality, Hercules is a family that prioritizes the health and well being of each person. Working for Hercules means you can focus on your career and your personal life. The team and management support the development of both your career and personal goals.

Explain the Hercules statement - ‘Your ethical wholesaler’

Ethics is part of everything we do. It is a conversation that our team always has present. Ethics is what drives us to do our job better. Knowing that Hercules always has the responsibility to speak out and carry the flag of ethics pushes us to be aware, focused, and successful with our partners so that we can continue to propagate change.

What have our partners said?

Many manufacturers have told me that they are now able to provide better services and assistance to patients because of the money they save working through Hercules. Manufactures also speak highly of how Hercules has given them back leverage in an industry that is constantly squeezing them of all their value.

What change has Hercules accomplished?

Hercules has reminded the industry that we exist to serve humans who are going through the toughest of times. I have seen the culture shift and people begin to make decisions based on the people that we serve. There is still a lot of work to do to effectuate systematic change but the change has been tangible and impactful.

Hercules Pharmaceuticals is proud to announce that its President Timothy Ward has been reappointed to the Board of Directors for the Partnership for DSCSA Governance (PDG). In November 2021, PDG held an election for seven board member positions for terms that will end in Q4 2023. Voting was open from November 7th, 2021 to November 19th, 2021.

It was announced the following members were elected to the board for a 2-year term beginning January 1st, 2022:

BOARD MEMBERS FOR 2022-2023 TERM

• Max Peoples, Uptown Pharmacy (Dispenser)
• Matt Hoover, Cleveland Clinic (Dispenser)
• Arthi Nagaraj, Sanofi (Manufacturer / Repackager)
• Mike Mazur, Pfizer (Manufacturer / Repackager)
• Liz Gallenagh, HDA (Wholesaler / 3PL)
• Matt Sample, AmerisourceBergen (Wholesaler / 3PL)
• Timothy M. Ward, Hercules Pharmaceuticals (At-Large)

Congratulations to all who were elected as we work together through PDG to develop a blueprint for interoperability for the DSCSA in 2023 to ensure the safety and security of our supply chain!

Hercules congratulates Kashyap Patel, MD, on being awarded the NCODA “Living the Mission” award and the success of his book Between Life and Death. The NCODA “Living the Mission Award” recognizes members who “exemplify the Mission and Values of NCODA in its quest to advance the value of dispensing practices for oncology physicians and deliver positive outcomes through collaboration in the care of oncology patients.”

Dr. Kashyap Patel is an experienced Chief Executive Officer and renowned oncologist currently serving as President at Community Oncology Alliance. He has a demonstrated history of over two decades of research, over 50 publications and presentations at both the national and international level, and leadership experience at the national level in the oncology field. Hercules strongly supports the work of Dr. Kashyap and his commitment to humanitarian endeavors.

Hercules comprehensively monitors the market and prepares for supply chain shortages to ensure a steady supply of pharmaceutical products for its customers. During the Azacytidine shortage, Hercules was able to identify and mitigate risks early through its diligent monitoring and proprietary supply chain analysis, enabling the team to reliably provide customers’ product supply throughout the market disruptions. Hercules continues to respond promptly to market conditions to ensure a secure supply of products for our customers.

There have been some exciting developments in PDG this June!

Since 2020, Hercules Pharmaceuticals has been an active member of The Partnership for DSCSA Governance (PDG) working to ensure the safety and security of our pharmaceutical supply chain.

On June 3rd, the FDA published four guidance documents for the DSCSA: the final guidance Product Identifiers Under the Drug Supply Chain Security Act, Questions and Answers, the final guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, the revised draft guidance Definitions of Suspect Product and Illegitimate Product for Verification Obligation under DSCSA, and the new draft guidance Enhanced Drug Distribution Security at the Package Level under DSCSA.

Hercules Pharmaceuticals will participate in PDG's discussions, focusing on analyzing the FDA’s guidance documents, especially as they relate to the enhanced system for interoperability. In Q3 of 2021, many of these planned discussions will focus on the new Enhanced Drug Distribution Security at the Package Level under DSCSA draft guidance. Hercules plans to submit comments to the FDA on both draft guidances.

We would also like to welcome VeV Scientific, Harmony Biosciences, InfiniTrack, Biocon Pharma Inc. and Vantage Solutions to PDG!

Concurrent to the call to action contained on numerous Presidential Executive Orders and Section 3202 of the Coronavirus Aid, Relief, and Economic Security Act, Hercules Pharmaceuticals has conducted an advanced national security analysis and geopolitical analysis of the U.S. pharmaceutical supply chain and shared this analysis with relevant touchpoints in U.S. Government.

We're proud of our Hofstra Alumni Brianni Lyons, who brings passion and talent to the Hercules team. In the article, Brianni, recalls her student years and the decisions that benefited her professional career, specifically the wide variety of experience during each semester, "The variety of my ensuing legal experience was a great competitive advantage to me for a career as a corporate lawyer, and it helped me to clearly identify my professional preferences and legal interests."

Read the Law News article here.

Hercules has invested in a multi-phase expansion for our cold chain capacity to meet the industry's demands. Hercules is an ISTA (International Safe Transit Association) member and an NABP accredited National Pharmaceutical Cold Chain distributor.

Hercules Pharmaceuticals announces that in March of 2020, its President Timothy M. Ward, Esq. has been appointed to the Board of Directors for the Partnership for DSCSA Governance (PDG). The PDG is an independent, balanced, sector-neutral, not-for-profit governance body that supports the secure, electronic, interoperable tracing and verification of prescription drugs in the U.S. Pharmaceutical Supply Chain as required by the Drug Supply Chain Security Act.

The topic for this timely event was 'COVID-19 - Diagnosing the new health and legal outlook.' Speakers focussed mainly on how COVID-19 has changed panelists' legal practices or careers. Hercules President Timothy M. Ward, Esq., touched upon the issues of COVID-19 exposing critical weaknesses in the U.S. healthcare supply chain and "deep systemic risk..." both domestically and with our trade partners.

Hercules President Timothy M. Ward, Esq., was invited to contribute to the NASP Conference in Washington, DC, on September 10th. Mr. Ward, who also serves on the Board of Directors of the National Association of Specialty Pharmacy, discussed 'Fulfillment: Aligning Processes to Best Standards of Care.'

Topics included: best practices on complying with the Drug Supply Chain Security Act, updates to prescription handling and cold chain management standards, and advancements in packaging, returns handling, and other areas of the fulfillment process. Hercules is a firm supporter of NASP and will continue to align our values with this reputable organization.

Timothy M. Ward, Esq. presented on biosimilars at the 2019 New York State Bar Association Annual Meeting FDA Law Section held on Thursday, January 17, 2019, at the New York Hilton Midtown. Timothy is President of Hercules Pharmaceuticals, a VAWD accredited national specialty distributor, and serves on the National Association of Specialty Pharmacy (NASP).

Before Hercules Pharmaceuticals, Tim was Chief Legal Officer of a multinational corporation, conducting business in highly regulated markets and directing the group's government affairs efforts. Tim has served on boards for numerous Washington DC trade and industry groups and participated in advisory committee capacity regarding economic sanctions, trade compliance, and foreign policy.

Hercules Pharmaceuticals is a wholesale distributor actively engaged in the political fight to return market-based economics to the drug supply chain and fight for transparency and fairness from the payor side. For more information about this event, visit www.nysba.org/AM2019